Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lomtegovimab - Boehringer Ingelheim

X
Drug Profile

Lomtegovimab - Boehringer Ingelheim

Alternative Names: BI-00767551; BI-767551; DZIF-10c; SARS-CoV-2-neutralising monoclonal antibody - Boehringer Ingelheim

Latest Information Update: 30 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator German Center for Infection Research
  • Developer Boehringer Ingelheim; German Center for Infection Research; University of Cologne
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections

Most Recent Events

  • 04 Oct 2021 Boehringer Ingelheim terminates phase II/III trials in COVID-2019 infections in Spain, Netherlands, Portugal, USA, Germany, Belgium, Denmark (IV) (Inhalation) in October 2021 not due to safety reasons (NCT04822701) (EudraCT2020-005588-29)
  • 22 Sep 2021 University of Cologne and Boehringer Ingelheim completes a phase I/IIa trial in COVID-2019 infections in Germany (Inhalation) (NCT04631705) (EudraCT2020-004448-27)
  • 11 Aug 2021 University of Cologne and Boehringer Ingelheim completes a phase I/IIa trial in COVID-2019 infections in Germany (IV) in August 2021 (NCT04631666; EudraCT2020-003503-34)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top